No Data
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $5
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE)
Fate Therapeutics: Hold Rating Amid Financial Stability and Upcoming Milestones
Leerink Partners Maintains Fate Therapeutics(FATE.US) With Buy Rating
Fate Therapeutics' Promising Outlook: Buy Rating on Innovative Cell Therapy Programs FT819 and FT522
Industry Analysts Just Made A Dazzling Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts